Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biomea Fusion, Inc. (BMEA : NSDQ)

• Company Description    Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California. Number of Employees: 106

• Price / Volume Information    Yesterday's Closing Price: $1.38 Daily Weekly Monthly 20 Day Moving Average: 3,559,479 shares Shares Outstanding: 59.51 (millions) Market Capitalization: $82.12 (millions) Beta: -0.12 52 Week High: $12.85 52 Week Low: $1.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.68% -34.02% 12 Week -16.87% -21.79% Year To Date -64.43% -68.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1599 Industrial Road - San Carlos,CA 94070 USA ph: 650-980-9099 fax: - ir@biomeafusion.com http://www.biomeafusion.com

• General Corporate Information    Officers Michael J.M. Hitchcock - Interim Chief Executive Officer; Director Rainer Erdtmann - Chief Operating Officer; Director Eric Aguiar - Director Bihua Chen - Director Sumita Ray - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077A106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 59.51 Most Recent Split Date: (:1) Beta: -0.12 Market Capitalization: $82.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 50.49% vs. Previous Quarter: 36.25% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -243.95 03/31/25 - -197.71 ROA 09/30/25 - - 06/30/25 - -140.74 03/31/25 - -134.84 Current Ratio 09/30/25 - - 06/30/25 - 3.68 03/31/25 - 2.25 Quick Ratio 09/30/25 - - 06/30/25 - 3.68 03/31/25 - 2.25 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.47 03/31/25 - 0.76 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©